Idenix Pharmaceuticals prices underwritten offering of common stock at $4.35 per share

Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten offering of 6,460,672 shares of its common stock at a price of $4.35 per share.  After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $26.2 million.  All of the shares are being sold by Idenix. The offering is expected to close on May 4, 2010, subject to customary closing conditions.